ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 733,50
0,00%
Dow Jones
43 487,83
0,78%
DAX
20 990,31
0,44%
Brent Oil
79,025
-0,25%
Bitcoin
102 262,02
0,23%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE

  6. Allergy Therapeutics Plc (AGY) Cours

Allergy Therapeutics Plc

Allergy Therapeutics Plc (AGY)

Argosy Minerals Inc
7,70
0,00
(0,00%)
Fermé 21 Janvier 5:30PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
7,70
Prix Achat
7,00
Prix Vente
8,00
Volume échangé
0,00
0,00 Fourchette du Jour 0,00
1,88 Plage de 52 semaines 7,71
Cap du marché
367,016M
Clôture Veille
7,70
Ouverture
-
Dernière Transaction
(O)
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
519 198
Actions en circulation
4 766 439 938
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-8,93
Bénéfice par action (BPA)
-0,01
Chiffre d'affairess
55,2M
Bénéfice net
-40,22M

À propos de Allergy Therapeutics Plc

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.allergytherapeutics.com
Siège social
West Sussex, Gbr
Fondé
-
Allergy Therapeutics Plc est coté dans le secteur Pharmaceutical Preparations de la London Stock Exchange avec le ticker AGY. Le dernier cours de clôture d'Allergy Therapeutics était de 7,70p. Au cours de la dernière année, les actions de Allergy Therapeutics ont été négociées dans une fourchette de prix de 1,88p à 7,71p.

Allergy Therapeutics compte actuellement 4 766 439 938 actions en circulation. La capitalisation boursière d'Allergy Therapeutics est de £367,02 million. Allergy Therapeutics a un ratio cours/bénéfice (ratio PE) de -8.93.

AGY Dernières nouvelles

Plus de nouvelles

Allergy Therapeutics PLC Director/PDMR Shareholding

Allergy Therapeutics PLC 15 January 2025     Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company")   PDMR Dealings   Issue of 687,500,000 Warrants     15 January 2025 - Allergy...

15 Janvier 2025
RNS Regulatory News

Allergy Therapeutics PLC Exercise of Options and Total Voting Rights

Allergy Therapeutics PLC 19 December 2024       Allergy Therapeutics plc   ("Allergy Therapeutics", or the "Group")   Exercise of Options and Total Voting Rights   19 December 2024 Allergy...

19 Décembre 2024
RNS Regulatory News

Allergy Therapeutics PLC Block Listing Interim Review

Allergy Therapeutics PLC 17 December 2024   Allergy Therapeutics plc   ("Allergy Therapeutics", "ATL" or the "Group")   Block Listing Interim Review     Name of applicant: ALLERGY THERAPEUTICS...

17 Décembre 2024
RNS Regulatory News

Allergy Therapeutics PLC Result of Annual General Meeting

Allergy Therapeutics PLC 16 December 2024     Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")   Result of Annual General Meeting     16 December 2024 Allergy Therapeutics plc...

16 Décembre 2024
RNS Regulatory News

Allergy Therapeutics PLC Positive Interim Data from PROTECT Trial

Allergy Therapeutics PLC 04 December 2024   Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group")   Allergy Therapeutics announces positive interim analysis data from the...

04 Décembre 2024
RNS Regulatory News

IN BRIEF: Allergy Therapeutics treats first patient in allergy trial

ics PLC - Sussex, England-based biotechnology company - Treats its first patient in the third phase of its paediatric ...

27 Novembre 2024
Alliance News

Allergy Therapeutics PLC First Patient Dosed in G308 Paediatric Trial

Allergy Therapeutics PLC 27 November 2024     Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group")   Allergy Therapeutics announces first patient treated in G308 Phase III...

27 Novembre 2024
RNS Regulatory News

Allergy Therapeutics PLC Submission of MAA for Grass MATA MPL

Allergy Therapeutics PLC 25 November 2024   Allergy Therapeutics plc ("Allergy Therapeutics" or "the Group")   Allergy Therapeutics Submits Marketing Authorisation Application for Grass MATA...

25 Novembre 2024
RNS Regulatory News

Allergy Therapeutics PLC Notice of 2024 Annual General Meeting

Allergy Therapeutics PLC 21 November 2024   Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company")   Notice of 2024 Annual General Meeting     21 November 2024 - Allergy...

21 Novembre 2024
RNS Regulatory News

Allergy Therapeutics annual loss narrows thanks to reduced expenses

Allergy Therapeutics PLC on Wednesday said it narrowed its loss during its most recent financial year despite a decli ...

06 Novembre 2024
Alliance News
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.456.206896551727.257.717.255358757.57439372DE
41.4523.26.257.716.246163427.19205039DE
122.75457.714.855191986.23734549DE
262.2541.28440366975.457.713.884162315.54051292DE
525.1196.1538461542.67.711.885963774.31310969DE
156-17.8-69.803921568625.526.750.855103843.80117355DE
260-3.65-32.158590308411.35400.854451269.04309241DE

AGY - Frequently Asked Questions (FAQ)

What is the current Allergy Therapeutics share price?
The current share price of Allergy Therapeutics is 7,70p
How many Allergy Therapeutics shares are in issue?
Allergy Therapeutics has 4 766 439 938 shares in issue
What is the market cap of Allergy Therapeutics?
The market capitalisation of Allergy Therapeutics is GBP 367,02M
What is the 1 year trading range for Allergy Therapeutics share price?
Allergy Therapeutics has traded in the range of 1,88p to 7,71p during the past year
What is the PE ratio of Allergy Therapeutics?
The price to earnings ratio of Allergy Therapeutics is -8,93
What is the cash to sales ratio of Allergy Therapeutics?
The cash to sales ratio of Allergy Therapeutics is 6,47
What is the reporting currency for Allergy Therapeutics?
Allergy Therapeutics reports financial results in GBP
What is the latest annual turnover for Allergy Therapeutics?
The latest annual turnover of Allergy Therapeutics is GBP 55,2M
What is the latest annual profit for Allergy Therapeutics?
The latest annual profit of Allergy Therapeutics is GBP -40,22M
What is the registered address of Allergy Therapeutics?
The registered address for Allergy Therapeutics is DOMINION WAY, WORTHING, WEST SUSSEX, BN14 8SA
What is the Allergy Therapeutics website address?
The website address for Allergy Therapeutics is www.allergytherapeutics.com
Which industry sector does Allergy Therapeutics operate in?
Allergy Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
0A2IH World Group Ltd
US$ 0,00
(0,00%)
0
0A2DCrh Plc
US$ 0,00
(0,00%)
0
0A2BBanco Bilbao Vizcaya Argentaria Sa
US$ 0,00
(0,00%)
0
0A22Anheuser Busch Inbev Nv
US$ 0,00
(0,00%)
9
0A1UUber Technologies Inc
US$ 68,55
(0,00%)
86
0A2IH World Group Ltd
US$ 0,00
(0,00%)
0
0A2DCrh Plc
US$ 0,00
(0,00%)
0
0A2BBanco Bilbao Vizcaya Argentaria Sa
US$ 0,00
(0,00%)
0
0A22Anheuser Busch Inbev Nv
US$ 0,00
(0,00%)
9
0A1UUber Technologies Inc
US$ 68,55
(0,00%)
86
0R0XTesla Inc
US$ 436,80
(0,00%)
24,2k
0R2VApple Inc
US$ 231,00
(0,00%)
23,52k
0R24Intel Corp
US$ 22,16
(0,00%)
22,85k
0XWGIqiyi Inc
US$ 12,70
(0,00%)
7,82k
0R1MExxon Mobil Corp
US$ 113,20
(0,00%)
5,84k

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

LSE
AGY
Allergy Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés